Clinical Trial Update: Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

View source ↗

Summary

This clinical trial update describes expanded-access use of itacitinib for a single patient with STAT1 gain-of-function disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stat1 Gain-of-function Disease

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: STAT1 Gain-of-Function Disease | Status: AVAILABLE